Tevogen ceo reaffirms the company's commitment to closing the information gap on its multi-billion-dollar assets, following the release of revenue projections

Warren, n.j., oct. 14, 2024 (globe newswire) -- tevogen bio (“tevogen” or “tevogen bio holdings inc.”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week's $1b+ revenue potential announcement.
GPS Ratings Summary
GPS Quant Ranking